Acadia pharmaceuticals announces top-line results from phase 3 advance-2 trial of pimavanserin in negative symptoms of schizophrenia

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) today announced top-line results from the phase 3 advance-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the negative symptom assessment-16 (nsa-16) total score (-11.8 vs. -11.1; p=0.4825; effect size=0.07). the safety and toler.
ACAD Ratings Summary
ACAD Quant Ranking